Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|2|4|485-500

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.2, Iss.4, 2002-01, pp. : 485-500

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of adeno-associated virus gene therapy vectors: a current evaluation

By Monahan Paul E   Jooss Karin   Sands Mark S  

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 79-91

Informa Healthcare

Access to resources Recommend Favorite

Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy

By  

Current Pharmaceutical Design, Vol. 21, Iss. 22, 2015-01 ,pp. : 3248-3256

Bentham Science Publishers

Access to resources Recommend Favorite

Biosafety of Recombinant Adeno-associated Virus Vectors

By  

Current Gene Therapy, Vol. 13, Iss. 6, 2013-01 ,pp. : 434-452

Bentham Science Publishers

Access to resources Recommend Favorite

Developing Immunologically Inert Adeno-Associated Virus (AAV) Vectors for Gene Therapy: Possibilities and Limitations

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 12, 2013-01 ,pp. : 1072-1082

Bentham Science Publishers

Access to resources Recommend Favorite

Comparative Study of Adeno-associated Virus, Adenovirus, Bacu lovirus and Lentivirus Vectors for Gene Therapy of the Eyes

By  

Current Gene Therapy, Vol. 17, Iss. 3, 2017-12 ,pp. : 235-247

Bentham Science Publishers

Access to resources Recommend Favorite